drugset
Drugs / GSK2982772
last change Oct 2021 re-read 3 minutes ago

GSK2982772

also known as CPD 5

Small molecule targets RIPK1 via inhibition

Developed for
psoriasis · rheumatoid arthritis · ulcerative colitis
Investigated by
GlaxoSmithKline · Clinical Unit at Cambridge (Addenbrooks) · Quotient Clinical · Quotient Sciences

Trials 9

today NCT04316585 · Ph 1 NCT03649412 · Ph 1 NCT03590613 · Ph 1 NCT03305419 · Ph 1 NCT03266172 · Ph 1 NCT02903966 · Ph 2 NCT02858492 · Ph 2 NCT02776033 · Ph 2 NCT02302404 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 16 trials
Phase 1 NCT04316585 Sep 2020 → Sep 2021 psoriasis GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT03649412 Sep 2018 → May 2019 autoimmune disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT03590613 Jul → Sep 2018 autoimmune disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT03305419 Oct 2017 → Oct 2018 autoimmune disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT03266172 Sep 2017 → Nov 2018 autoimmune disease GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT02302404 Jan 2015 → Mar 2016 inflammatory bowel disease GlaxoSmithKline Completed No outcome recorded
Phase 23 trials
Phase 2 NCT02903966 Nov 2016 → Jun 2019 ulcerative colitis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT02858492 Oct 2016 → Oct 2018 rheumatoid arthritis GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT02776033 Aug 2016 → Jan 2018 psoriasis GlaxoSmithKline Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as GSK2982772 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02302404 ↗
8

NCT03266172 ↗

NCT03649412 ↗

NCT02776033 ↗

NCT03305419 ↗

NCT03590613 ↗

NCT02903966 ↗

NCT04316585 ↗

NCT02858492 ↗
Known as CPD 5 ChEMBL registry synonym — accepted as the source's own label CHEMBL4071864 ↗
Action Inhibit “GSK2982772 is a highly selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) being developed to treat chronic inflammatory diseases.” PMID 29226626 ↗ Dec 2017
Modality Small molecule “GSK2982772 is an oral small-molecule RIPK1 inhibitor” PMID 33165774 ↗ Jan 2021
Route Oral “Administered orally with water for dosing from 5 to 120 mg” NCT02302404 ↗
Target RIPK1 “GSK2982772 is a highly selective inhibitor of receptor-interacting protein kinase 1 (RIPK1) being developed to treat chronic inflammatory diseases.” PMID 29226626 ↗ Dec 2017